The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about BELLUS’s business, operations, drug products, drug product development, competition, and present and future business prospects. Specifically, the Complaint alleges Defendants misrepresented and/or failed to disclose that BLU-5937’s “high selectivity” contributed to the drug potentially being less efficacious and thus likely unable to meet the primary endpoint of the Company’s Phase 2 study.